RT Book, Section
A1 Condon, Sean C.
A1 Isada, Carlos M.
A1 Tomecki, Kenneth J.
A2 Kang, Sewon
A2 Amagai, Masayuki
A2 Bruckner, Anna L.
A2 Enk, Alexander H.
A2 Margolis, David J.
A2 McMichael, Amy J.
A2 Orringer, Jeffrey S.
SR Print(0)
ID 1161343556
T1 Systemic and Topical Antibiotics
T2 Fitzpatrick's Dermatology, 9e
YR 2019
FD 2019
PB McGraw-Hill Education
PP New York, NY
SN 9780071837798
LK dermatology.mhmedical.com/content.aspx?aid=1161343556
RD 2024/04/24
AB AT-A-GLANCEEmpiric  therapy  for  skin  and  soft-tissue  infections  (SSTIs)  is  usually  successful.β-Lactam  antibiotics  (penicillins  and  cephalosporins)  and  clindamycin  are  first  line  options  for  empiric  therapy  for  mild  and  moderate  nonpurulent  SSTIs.Antibiotic  resistance  is  a  growing  concern.  Culture  and  sensitivity  help  to  define  better  management.Empiric  therapy  for  moderate  and  severe  purulent  SSTIs  should  cover  methicillin-resistant  Staphylococcus  aureus  (MRSA).β-Lactam  antibiotics  and  vancomycin  inhibit  bacterial  cell  wall  synthesis.Several  antibiotic  classes  interfere  with  bacterial  protein  synthesis  by  binding  ribosomal  subunits:  tetracyclines  at  30S;  lincosamides  (clindamycin),  macrolides,  streptogramins,  and  oxazolidinones  (linezolid)  at  50S.New  agents  for  SSTIs  include  ceftaroline,  lipoglycopeptides  (dalbavancin,  oritavancin,  and  telavancin),  and  oxazolidinones  (tedizolid).Topical  antibiotics  may  negate  the  need  for  systemic  antibiotics  in  the  treatment  of  impetigo;  they  are  unnecessary  as  postsurgical  prophylaxis  to  prevent  wound  infection.